Benjamin Tate Suratt MD
Critical Care Medicine
Director, Early Development, Immunity & Inflammation, Sanofi
Join to view full profile
6 Deer Crossing LnEssex Junction, VT 05452
Dr. Suratt is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Benjamin Suratt is a pulmonologist in Essex Junction, VT. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 26 years. He specializes in critical care medicine and is experienced in critical care medicine, acute lung injury, and cancer survivorship.
Education & Training
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993, MD, AOA
Amherst CollegeBA, Interdisciplinary , summa cum laude, 1984 - 1988
Certifications & Licensure
VT State Medical License 2002 - 2026
CO State Medical License 1998 - 2003
MA State Medical License 1995 - 1998
American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Syndromic Surveillance Reporting, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beaker Reportable Labs Reporting, Epic Systems Corporation, 2013-2017
Publications & Presentations
PubMed
- 2 citationsRilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.Jorge F Maspero, Ian D Pavord, Michael E Wechsler, William Busse, Tanya M Laidlaw
The Lancet. Respiratory Medicine. 2026-05-01 - 24 citationsA proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule.Annemie Deiteren, Emmanuel Krupka, Lieselot Bontinck, Karine Imberdis, Griet Conickx
The European Respiratory Journal. 2025-04-01 - 28 citationsA first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers.Annemie Deiteren, Lieselot Bontinck, Griet Conickx, Marie Vigan, Nele Dervaux
Clinical and Translational Science. 2024-06-01
Press Mentions
- In ARDS, Heterogeneity = OpportunityApril 4th, 2017
Grant Support
- Klebsiella Pneumoniae Pathogenesis in the Obese LungNational Institute of Allergy and Infectious Diseases2020–2022
- Ketone Body Supplementation in Obese AsthmaNational Heart, Lung, And Blood Institute2018–2022
- Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)National Heart, Lung, And Blood Institute2018–2022
- Developing obese mouse models of Pseudomonas aeruginosa pneumoniaNational Institute of Allergy and Infectious Diseases2015–2017
- Serum Amyloid A3 in Allergic Asthma: An Endogenous Mediator of Disease SeverityNational Heart, Lung, And Blood Institute2012–2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
